To improve breast cancer diagnosis, 2 prospective clinical trials were conducted to test (n [ 351) and validate (n [ 210) Videssa Breast. If used in conjunction with imaging, Videssa Breast could have reduced unnecessary biopsies by up to 67%. These results support the joint use of breast imaging and Videssa Breast to better inform clinical decisions for women under age 50. Background: Despite significant advances in breast imaging, the ability to detect breast cancer (BC) remains a challenge. To address the unmet needs of the current BC detection paradigm, 2 prospective clinical trials were conducted to develop a blood-based combinatorial proteomic biomarker assay (Videssa Breast) to accurately detect BC and reduce false positives (FPs) from suspicious imaging findings. Patients and Methods: Provista-001 and Provista-002 (cohort one) enrolled Breast Imaging Reporting and Data System 3 or 4 women aged under 50 years. Serum was evaluated for 11 serum protein biomarkers and 33 tumor-associated autoantibodies. Individual biomarker expression, demographics, and clinical characteristics data from Provista-001 were combined to develop a logistic regression model to detect BC. The performance was tested using Provista-002 cohort one (validation set). Results: The training model had a sensitivity and specificity of 92.3% and 85.3% (BC prevalence, 7.7%), respectively. In the validation set (BC prevalence, 2.9%), the sensitivity and specificity were 66.7% and 81.5%, respectively. The negative predictive value was high in both sets (99.3% and 98.8%, respectively). Videssa Breast performance in the combined training and validation set was 99.1% negative predictive value, 87.5% sensitivity, 83.8% specificity, and 25.2% positive predictive value (BC prevalence, 5.87%). Overall, imaging resulted in 341 participants receiving follow-up procedures to detect 30 cancers (90.6% FP rate). Videssa Breast would have recommended 111 participants for follow-up, a 67% reduction in FPs (P < .00001). Conclusions: Videssa Breast can effectively detect BC when used in conjunction with imaging and can substantially reduce unnecessary medical procedures, as well as provide assurance to women that they likely do not have BC.
Introduction
Breast cancer (BC) is predicted to be the second leading cause of cancer deaths in women in the United States; approximately 232,000 cases of invasive BC and 60,000 cases of ductal carcinoma in situ (DCIS) are diagnosed and 40,000 deaths occur annually. 1 However, if diagnosed early in a localized state, 5-year survival rates are > 98%. 2 Imaging (including mammography, ultrasound [US] , magnetic resonance imaging [MRI] , and 3-D tomosynthesis) is the gold standard for BC detection. It has been suggested that imaging ambiguity could be mitigated by the combination of a proteomic assay. 3 When imaging results are questionable (eg, Breast ImagingReporting and Data System [BI-RADS] categories 3 or 4), National Comprehensive Cancer Network guidelines recommend that BI-RADS 3 patients are followed with reimaging at 6 months, and BI-RADS 4 patients are recommended for biopsy. 4 Confounding factors (eg, breast density, prior biopsy, and lesion size) may limit the effectiveness of imaging. [5] [6] [7] Women with high breast density have a greater incidence of BC compared with women with low density. 5, 8 Despite recent advances in imaging, the rates of false positives (FPs) and false negatives (FNs) represent a significant problem in the early diagnosis of BC. [9] [10] [11] [12] The sensitivities and specificities of various imaging modalities and/or their various combinations widely range from 50% upwards. [13] [14] [15] [16] [17] A comprehensive study by Berg et al evaluated the supplemental cancer detection yield of US or MRI, when used in addition to mammography, in a large cohort of women (n ¼ 2809; 21 sites) at elevated risk for BC. 15 In this study, sensitivity ranged from 52% upwards and specificity ranged from 65% upwards, depending on the imaging modality used. The addition of screening US or MRI to mammography resulted in more cancers being detected, but there was also an increase in the number of FPs. 15 In recent years, the role of protein biomarkers in the detection of BC has undergone a major shift from investigational use to evaluation of prognostic value for a given BC subtype. 11 With the discovery of key protein biomarkers and protein signatures for BC, proteomic technologies are currently poised to serve as an ideal diagnostic adjunct to imaging. 3, 18 Previous research studies have
shown that breast tumors are associated with systemic changes in both serum protein biomarkers (SPBs) and tumor-associated autoantibodies (TAAbs). [19] [20] [21] [22] [23] [24] [25] [26] [27] A very limited number of protein biomarkers, such as the estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, cancer-associated antigens (CA27.29 and CA15-3), and carcinoembryonic antigen are currently used for prognosis and treatment monitoring, but their utility in detecting early BC has not been confirmed. 28, 29 In Figure 1 Provista-001 and Provista-002 Cohort One (Clinicaltrials.gov Identifiers NCT01839045 and NCT02078570 Given the complexity and heterogeneity of BC, the use of individual protein biomarkers has lacked sensitivity and specificity; a combinatorial biomarker approach may be warranted to ensure the greatest success in detecting BC. 3 Therefore, to address the unmet needs of the current BC detection paradigm in patients under the age of 50 years assessed as BI-RADS 3 or 4, the aim of this study was to develop a combinatorial proteomic biomarker assay comprised of SPBs and TAAbs, integrated with patient-specific clinical data, to produce a diagnostic score that could reliably detect BC following suspicious imaging findings.
Patients and Methods

Study Design and Participants
Provista-001 (Clinicaltrials.gov, NCT01839045) and Provista-002 (cohort one; Clinicaltrials.gov, NCT02078570), which were sponsored by Provista Diagnostics, enrolled women assessed as either a BI-RADS 3 or 4 at the time of enrollment. All imaging modalities, such as mammography, 3-D tomosynthesis, US, and MRI (and any combination of these modalities) were permitted for the assessment of BI-RADS. Participants were enrolled across 13 domestic clinical sites (See Supplemental Table 1 in the online version), and the study was institutional review board-approved. Informed consent was obtained from all study participants prior to enrollment and sample collection. Blood samples were collected post-imaging and pre-biopsy for all patients enrolled in this study to minimize any potential collection-associated variation. Participants who were not diagnosed with BC were followed for 6 months for additional clinical outcomes, which were assessed via additional imaging and/or pathology results.
Videssa Breast results were not shared with clinicians during the trials to ensure that clinical decision-making was unaffected. An overview of the study design is provided in Figure 1 , and the clinical management workflow is summarized in Figure 2 . The study was designed by an external subject-matter expert and the authors, and a third-party Contract Research Organization collected and monitored data.
Study Objective
The aim of this study was to develop a blood-based diagnostic test to detect BC for use in conjunction with imaging to aid healthcare providers in making informed decisions on treating young women (under 50 years of age) with difficult-to-assess imaging findings.
Measurement of SPBs and TAAbs
Serum was evaluated for the concentrations of 11 SPBs and for the relative presence/absence of 33 TAAbs (See Supplemental  Table 2 in the online version). Following informed consent and prior to biopsy, 5 tubes of blood were collected in a Vacutainer clot tube. Blood was allowed to coagulate for 30 minutes at room temperature, then placed in a centrifuge and spun at 1100Â g for 10 SPB concentrations were determined using modified electrochemiluminescent-based enzyme-linked immunosorbent assay kits, following manufacturer's specifications (Meso Scale Discovery, Rockville, MD). 32 Each SPB plate contained 6 vendor-provided standards (in duplicate) to generate a standard curve. TAAbs were detected using an indirect enzyme-linked immunosorbent assay, which includes binding purified recombinant proteins to standardbind plates (Meso Scale Discovery). Proteins were diluted in 1 Â phosphate-buffered saline and coated onto blank plates at a final concentration of 20 ng/well. All recombinant proteins, certified as > 80% pure (sodium dodecyl sulfate polyacrylamide gel electrophoresis), were purchased from Origene (Rockville, MD) or Abnova (Taiwan). Origene proteins were myc/DDK peptide-tagged and produced in HEK293 cells. Abnova proteins were glutathione S-transferase-tagged and produced in wheat germ cells. All samples were processed in duplicate both for SPBs and TAAbs, and mean values were used for data analysis. Appropriate controls (samples with known values, standards, and blanks) were included on each plate to monitor the performance of both assays. SPB concentrations were calculated by processing sample and standard data with the Meso Scale Discovery Workbench 4.0 software using a weighted, 4-parameter, logistic-fit (FourPL) algorithm. TAAb ratio values were determined using the following calculation, using normalization parameters modified from Anderson et al 
Statistical Analysis
Using the Provista-001 dataset only (Figure 1 ), training models to predict the presence or absence of BC were developed using the individual biomarkers (ie, SPBs and TAAbs). Owing to expectedly weak univariate associations between individual biomarkers based on previous studies, 34, 35 additional training models with and without participant's specific clinical data were built iteratively by altering SPB and TAAb features. Multivariable models were built using forward and backward selection methods and varying the alpha for inclusion in (or exclusion from) a model to identify a subset of predictors that consistently presented. These multivariable models were optimized by adding and subtracting additional markers iteratively, until a final model was created that met minimum performance criteria. The area under the receiver operating characteristic was used to determine model performance in regards to sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV); Table 1 provides definitions for these terms. Confidence intervals were reported as 2-sided binomial 95% confidence intervals. A logistic regression model, which included participant age, was created to combine a panel of transitions that were modeled to calculate a diagnostic score (D s ) between 0 and 1 for each sample, as follows:
where D s is diagnostic score, a is intercept, b 1 is coefficient for age, b i is the coefficient for SPB, and b j is the coefficient for TAAb. Samples with D s equal to or greater than the reference value (cutoff) were considered clinically positive (BC), and samples that were less than the reference value were clinically negative (benign).
This training model was tested using the validation set, Provista-002 cohort one ( Figure 1) . This model was then applied to the combined training (Provista-001) and validation (Provista-002) sets to evaluate its performance in a larger dataset.
Participant characteristics were summarized with medians and inter-quartile ranges for numerical data, or sums and percentages for categorical data. To determine balance between sets, Wilcoxon ranksum tests were used for continuous variables and c The proportion of subjects without the disease who had a negative test.
tests or Fisher
The proportion of subjects with disease but who had a negative test result.
The proportion of subjects without disease who had a positive test result.
The proportion of subjects with a positive test result who actually have the disease.
The proportion of subjects with a negative test result who do not have disease.
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Results
Study Population
The Provista-001 study enrolled 351 women under the age of 50 years at 8 sites (See Supplemental Table 1 in the online version) across the United States, who were assessed as either BI-RADS category 3 or 4 at the time of enrollment. Blood samples were collected post-imaging and pre-biopsy for all patients enrolled in this study to minimize any potential collection-associated variation (Figure 2 ). Of the 351 participants enrolled, samples collected from 12 participants had to be excluded from analysis (Figure 1 ), resulting in 339 participants being analyzed for biomarker expression ( Table 2) . Of these 339 participants, 313 were diagnosed with a benign breast condition, either by biopsy during the initial visit or by additional imaging performed at the 6-month follow-up. Twenty-six participants were diagnosed as having invasive BC (18) or DCIS (8); thus, cancer incidence was 7.7% in Provista-001 (26/ 339) ( Table 2 ). Of these, 24 participants were diagnosed at the primary visit, and an additional 2 participants were diagnosed during the 6-month follow-up visit.
The Provista-002 study enrolled 210 women under the age of 50 years at 10 sites (See Supplemental Table 1 Liquid Table 2) . Of these 206 participants, there were 200 diagnosed with a benign breast condition, either by biopsy during the initial visit or by additional imaging performed at the 6-month follow-up visit. Six participants were diagnosed as having BC: BC (2) or DCIS (4). Thus, cancer incidence was 2.9% in the Provista-002 cohort one dataset (6/206) ( Table 2) . Of these, all participants were diagnosed at the primary visit, and no additional BC cases were diagnosed during the 6-month follow-up visit. Serum samples were collected post-BI-RADS assessment but prior to biopsy (Figure 2 ). Samples were evaluated for SPB and TAAb expression as described in the Methods section, and these biomarker expression data were used for Videssa Breast model development.
Videssa Breast Model Development
Previously published results 34 suggested several SPBs (eg, OPN, FASL, TNF-a, carcinoembryonic antigen, IL12, HGF, and VEGFD) and TAAbs (eg, FRS3, RAC3, HOXD1, GPR157, ZMYM6, EIF3E, CSNK1E, ZNF510, BMX, SF3A1, and SOX2) that demonstrated a modest ability to distinguish benign from BC patients. Thus, models were developed using these preselected biomarkers 23, 34 (See Supplemental Table 2 in the online version).
These preselected markers were univariately evaluated in benign and BC populations; representative box-plots using both age-and BI-RADS-matched samples are provided in Supplemental Figure 1 (in the online version). Because this preselected group of markers was developed utilizing retrospectively collected specimens from 1 group of patients from a single clinical site, 24 ,34 the inclusion of additional markers was predicted to improve the detection of BC. Additionally, as the prospective cohorts described in this study only included patients with BI-RADS category 3 and 4 diagnoses, these samples represent an intended-use population different than previous studies, which included additional BI-RADS groups 0, 1, 2, 3, 4, and 5 and was not limited to patients aged under 50. The collection of samples from a separate intended-use population further added to the rationale of altering markers to model development.
To develop models that could detect the presence or absence of BC in women under the age of 50 years scored as BI-RADS category 3 or 4, a multi-step process was utilized, whereby biomarker expression and clinical characteristics of the Provista-001 participants (n ¼ 339) were analyzed using logistic regression modeling, 36, 37 as described in the Methods.
Several training models to detect BC were assessed using different protein biomarker combinations (SPBs and TAAbs) with and without demographics and clinical characteristics, such as age, race, family history, and smoking status (multiple other characteristics were tested but did not show significant differences). Models involving either SPBs or TAAbs alone did not provide statistically significant results (See Supplemental Figure 2 in the online version). The SPB model alone (6 markers) demonstrated high sensitivity (88.5%) and the TAAb model alone (10 markers) demonstrated high specificity (82.5%); these findings confirmed our previous results 34 ; therefore, we deduced that combining SPB and TAAb biomarkers would result in a model with higher specificity and higher sensitivity than either biomarker type alone. Starting with our retrospective model, 34 combinatorial training models were built 
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Clinical Breast Cancer November 2017 -521 using both forward and backward selection methods to identify a subset of markers that consistently entered models at various alphas. We then iteratively included or excluded SPB (11) and TAAb (33) markers to optimize sensitivity and specificity while being as parsimonious as possible. No other participant demographic data, except for age, improved the model performance.
The training model consisted of 18 protein biomarkers (8 SPBs and 10 TAAbs) identified from the original set of biomarkers evaluated in this study (See Supplemental Table 2 in the online version). The performance of this model in the training dataset (Provista-001; n ¼ 339) was 92.3% for sensitivity, 85.3% for specificity, 99.3% for NPV, and 34.3% for PPV (Figure 3) . Provista-002 (cohort one; n ¼ 206) used an independent validation set. The training model was locked (ie, biomarker composition, coefficient values, and cut-off point used to detect the presence or absence of cancer) before clinical outcome data for the validation set (Provista-002 cohort one) was received from the blinded data broker. The training model developed using the training set (n ¼ 339) was applied to the validation set (n ¼ 206) to detect BC. A summary of the performance data is provided in Figure 3 . The performance of Videssa Breast, when prospectively applied to the validation set (Provista-002 cohort one; n ¼ 206), demonstrated a 66.7% sensitivity, 81.5% specificity, 98.8% NPV, and 9.8% PPV (Figure 3 ). NPV and specificity are measures of the number of true negative cases within a population. The NPV (98.8%) for Videssa Breast remained extremely high for the validation cohort, which was comparable with the NPV observed for the training set (99.3%; P ¼ .3023). The same is true for specificity, which decreased only slightly in the validation cohort (85.3% in training and 81.3% in validation; P ¼ .24459).
All benign cases were included in both the training and validation sets, regardless of whether the subject received a biopsy. Of the benign samples collected for this study, 43% were presumed to be benign (ie, no pathologic confirmation by biopsy) (Figure 2 ), and this included both BI-RADS category 3 and 4 subjects, irrespective of National Comprehensive Cancer Network guidelines, which recommend that BI-RADS 3 patients are followed with reimaging at 6 months, whereas BI-RADS 4 patients are recommended for biopsy. 4 Following model development, performance was specifically evaluated in the confirmed benign (ie, by biopsy) (Figure 2 ) and BC subgroups (See Supplemental Table 3 in the online version). Sensitivity was unaffected and specificity was increased in both training and validation sets, which could be because of the reduction in FPs (Compare Figure 1 with Supplemental Table 3 [in the online version]). NPV slightly decreased (P ¼ .82287) and PPV increased (P ¼ .00101) in this subset analysis. These results demonstrate consistent model performance within the intended-use population (where the subject may not undergo biopsy), as well as in the clinically confirmed population (Figure 2 ). Owing to low cancer prevalence, both the training (Provista-001) and validation (Provista-002) data sets were combined to assess overall Videssa Breast performance (combined BC prevalence, 5.87%). Videssa Breast correctly diagnosed 28 of the 32 participants with BC (See Supplemental Table 4 in the online version), with a NPV of 99.1%, sensitivity of 87.5%, specificity of 83.8%, PPV of 25.2%, and an area under the curve of 0.8477 (Figure 3) . Because of the higher BC prevalence in the training set, it is possible that the sensitivity may suffer from optimism bias; however, specificity and NPV were not impacted. Of note, there were 2 cases that Videssa Table 4 in the online version]), and these cases were not recommended for biopsy after imaging. Subsequent imaging at follow-up recommended these cases for biopsy, and biopsy subsequently confirmed that cancer was present. Thus, Videssa Breast may provide additional diagnostic power to detect early cases of BC.
Detailed timelines for 2 subjects are shown in Figure 4 . Subject 6043 was assessed as BI-RADS 3 on initial visit, and no biopsy was 
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performed. At the 6-month follow-up visit, the subject was assessed as BI-RADS 4, and a subsequent biopsy revealed a high-grade DCIS. Videssa Breast was run on serum drawn at the initial visit and at the 6-month follow-up visit. Both samples resulted in a positive Videssa Breast test result, indicating that this test had correctly identified the subject as likely having BC at the initial visit, when standard assessments failed to detect the presence of BC. Another case, Subject 2004, was assessed as BI-RADS 4 at the initial visit; this subject's Videssa Breast test result was positive. The subject's biopsy revealed a low-grade DCIS; however, an additional biopsy 14 days later revealed a grade 2 BC, indicating that both imaging and Videssa Breast correctly identified the subject as likely having breast adenocarcinoma. Indeed, in this study, when imaging and Videssa concord, 100% detection was observed at the earliest stage.
Comparison of Videssa Breast to Imaging-Based Assessment on Medical Procedure Rate
The imaging modalities used to diagnose BC in participants enrolled in this clinical trial included diagnostic mammogram, US, diagnostic mammogram combined with US, tomosynthesis, and/or MRI. The FP rate (defined as the identification of a benign breast condition by biopsy) of imaging at enrollment was compared with the potential FP rate for Videssa Breast (Table 3) . Imaging contributed to 339 participants receiving procedures and detected 30 cancers at enrollment, resulting in 309 FPs (91% FP rate). If Videssa Breast had been used in assessment at the time of enrollment, it would have recommended 111 participants receive procedures, of which 83 would have resulted in a FP (75% FP rate). These data suggest that Videssa Breast, when used in conjunction with imaging, can reduce unnecessary biopsies by up to 67% (P .00001) compared with imaging modalities alone.
Discussion
In women with questionable or equivocal imaging findings, it is often difficult to determine whether to proceed with biopsy, further image, or reassess at a later time. Of particular concern is the high FP rate associated with BI-RADS 3 or 4 patients, who are either followed with repeat imaging assessment at 6 months or recommended for biopsy, respectively. The economic impact of FPs is multiplicative owing to the cascade of follow-up diagnostic procedures, such as additional imaging/biopsy, resulting in cumbersome and costly follow-ups. In addition, these follow-up procedures may impact the quality of life for the patient (eg, missing work and family time). Furthermore, scar tissue remaining from biopsy can pose additional complications for future imaging. Perhaps more importantly, the anxiety and negative impact of a positive diagnosis (false or not) on the quality of life for patients is significant and may impact further compliance. Thus, there is a clear need for a diagnostic test that reduces FPs and provides a tool for clinicians to confirm negative findings.
Based on previously published studies suggesting the clinical value of SPBs and TAAbs, 3 we conducted a prospective study to determine if the diagnosis of BC could be improved through the complementary use of a combinational proteomic biomarker assay with imaging. Videssa Breast was successfully developed and validated by combining 8 SPBs and 10 TAAbs with participants' demographic and clinical data; the NPV was 98.8%, sensitivity was 66.7%, specificity was 81.5%, and PPV was 9.8% in the validation set.
We note a decrease in clinical sensitivity between the training and validation sets. Although possibly because of over-fitting of the training model, we feel the bulk of the reduction in Videssa Breast sensitivity in the validation cohort is likely owing to the marked reduced BC prevalence in the Provista-002 cohort as compared with the training set (7.7% vs. 2.9% for Provista-001 and Provista-002, respectively) ( Table 2 ). This reduction may be because of changes in imaging assessments (as a means of decreasing imaging-related FN rates) as this has now been observed in greater than 1350 patients enrolled in Provista's prospective clinical trials over a period of 3 years. Other large studies have also seen a decrease in BI-RADS category 3 use and have witnessed increased BI-RADS category 4 assessment, likely owing to medicolegal considerations. Because sensitivity and PPV were impacted, whereas specificity and NPV were not, it is likely that the decrease in sensitivity and PPV were attributed to low BC prevalence and not over-fitting.
Of the 32 cancers detected by imaging, 2 patients were not recommended for follow-up procedures at enrollment, whereas A significant limitation of this study is that the confirmation of BC through biopsy is subject to sampling bias. A patient can be diagnosed with BC only if the biopsy comes from a region of the breast that includes cells with abnormal lesions. If a biopsy is not performed or is performed in a location absent of neoplasm, BC could be incorrectly diagnosed as a benign breast condition. For example, one of the participants in this study, Subject 1021, was assessed as BI-RADS 4 at the initial visit and underwent a cyst aspiration. Videssa Breast testing on both the initial serum sample and the 6-month follow-up serum sample revealed high levels of p53 TAAb, which is highly indicative of cancer based on previous literature. 38 Upon further review of the patient's medical history, it was noted that this participant had 2 second-degree relatives and 1 first-degree relative diagnosed with BC. There is the possibility that this participant had early BC at the initial visit. When patients have both a positive protein signature for Videssa Breast and a family history of BC, this may warrant additional monitoring-thus, Videssa Breast appears to have utility in aiding physicians to more effectively manage these patients. Another limitation of this study is that patients were followed for 6 months rather than a 12-month follow-up. A 6-month follow-up period may not be sufficient to identify all cancers in BI-RADS 3 and 4 patients; an additional 12-month follow-up may have yielded an increased cancer incidence. Therefore, it is possible that a subset of the Videssa Breast FPs are pre-clinical BCs that have yet to be detected. This study also relied on multiple imaging modalities to detect BC. The differential diagnostic methodologies used for patients in this clinical trial may have impacted the performance of Videssa Breast, as these methodologies widely vary in their sensitivity and specificity. 15 An additional study limitation is the BC prevalence in the Provista-002 cohort one set. Whereas a BC prevalence of 20% was expected based on literature, 39 the actual prevalence was 7.7% for Videssa Breast in Provista-001 (training set) and 2.9% for Provista-002 cohort one (validation set). Despite a reduction in sensitivity for the validation set (likely owing to the reduction in BC prevalence from 7.7% to 2.9% for the training and validations sets, respectively), Videssa Breast continued to demonstrate specificity (81.5%) and NPV (99.1%) in this independent validation set. These data provide quantifiable metrics supporting that Videssa Breast can reduce diagnostic uncertainty for providers, based on Videssa Breast specificity, and provide assurance to patients, based on Videssa Breast NPV, that they do not have BC. Thus, Videssa Breast could ultimately reduce the number of unnecessary medical procedures (ie, follow-up imaging and biopsies) and alleviate the stress of not knowing whether an abnormal imaging finding is a BC. Additional studies are being conducted to determine how to best maximize sensitivity (an optimal model for biopsy rule-out) and potential medical cost-savings associated with Videssa Breast in women over age 50.
Conclusion
In summary, this study describes the development of an innovative, noninvasive, actionable tool to detect BC in women under the age of 50. To our knowledge, this is the first prospective study of a proteomic panel (composed of SPBs and TAAbs) being used in the precise detection of BC in woman with questionable imaging findings. Videssa Breast can be used concomitantly with imaging to help guide the management of women under the age of 50 with challenging imaging findings. The test exhibited consistently high specificity and NPV in all test sets in a prospective manner, further supporting its clinical use in this intended-use population (BI-RADS 3 or 4). Further studies evaluating whether Videssa Breast performs similarly in broader age ranges, high-risk populations, and additional BI-RADS-defined patients will be important in assessing the totality of its clinical utility and expanding the clinical use of this personalized, precise, proteomic clinical assay. Additional model development is currently being conducted to maximize sensitivity, thereby increasing clinical utility as a biopsy rule-out test.
Clinical Practice Points
This study describes the development of an innovative, noninvasive, actionable tool, Videssa Breast, to detect BC in women of low-or intermediate risk (BI-RADS 3 or 4) and under the age of 50. To our knowledge, this is the first prospective study of a proteomic panel (composed of SPBs and TAAbs) being used in the precise detection of BC in woman with questionable imaging findings. The test exhibited consistently high specificity and NPV in all test sets in a prospective manner, further supporting its clinical use in this intended-use population. In women with questionable or equivocal imaging findings, it is often difficult to determine whether to proceed with biopsy, further image, or reassess at a later time. Of particular concern is the high FP rate associated with BI-RADS 3 or 4 patients, who are either followed with repeat imaging assessment at 6 months or recommended for biopsy, respectively. If used prospectively in conjunction with imaging, Videssa Breast could have reduced unnecessary biopsies by up to 67%, compared with standard imaging modalities (P < .0001). Therefore, this study supports the use of Videssa Breast, concomitantly with imaging, to help guide the management of women under the age of 50 with challenging imaging findings.
institutional review boards for each site are provided in Supplemental Table 1 (in the online version). All participants were provided with informed consent and agreed to study participation prior to sample collection.
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